Vinflunine in the Τreatment of Upper Tract Urothelial Carcinoma – Subgroup Analysis of an Observational Study

Heers, Hendrik; Geeter, Patrick de; Goebell, Peter J.; Matz, Ullrich; Schultz, Wito de; Edlich, Birgit; Retz, Margitta; Hegele, Axel

doi:10.21873/anticanres.12098

Search citation statements

Order By: Relevance

Paper Sections

Select...

Second-line Setting1

Chemotherapy1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(2 citation statements)

References 18 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to the bladder cancer setting, second-line treatment of metastatic UTUC remains challenging. In a post hoc subgroup analysis of locally advanced or metastatic UC, vinflunine was reported to be as effective in UTUC as in bladder cancer progressing after cisplatin-based chemotherapy [203]. More importantly, a phase III RCT including 542 patients who received prior platinum-based chemotherapy for advanced UC showed that pembrolizumab could decrease the risk of death by almost 50% in those with UTUC (n = 75, 13.8%), although these results were borderline significant [204].…”

Section: Second-line Settingmentioning

confidence: 99%

European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update

et al. 2023

View full text Add to dashboard Cite

Section: Second-line Settingmentioning

confidence: 99%

European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update

et al. 2023

View full text Add to dashboard Cite

“…In 2015, a prospective, observational study investigated the safety and efficacy of vinflunine in patients pre-treated with platinum-based chemotherapy [75]. Vinflunine was administered in the second line setting to 51 (66%) of the 77 patients.…”

Section: Chemotherapymentioning

confidence: 99%

Clinical and Biological Differences between Upper Tract Carcinoma and Bladder Urothelial Cancer, Including Implications for Clinical Practice

Lefort,

Rhanine,

Larroquette

et al. 2023

Cancers

View full text Add to dashboard Cite

Upper tract urothelial carcinoma (UTUC) is a rare disease included, along with the much more frequent urothelial bladder cancer (BUC), in the family of urothelial carcinomas (UCs). However, while UTUCs and BUCs share several features, their epidemiological, clinical, pathological, and biological differences must be considered to establish an optimal therapeutic strategy. This review examines the clinical differences between UTUC and BUC, as well as the main results obtained by molecular screening of the two diseases. The findings of clinical trials, performed in peri-operative and metastatic settings and assessing systemic treatments in UC, are summarised. A comparison of the data obtained for UTUC and BUC suggests improved therapeutic approaches, both in regards to routine practice and future drug development.

show abstract

Vinflunine in the Τreatment of Upper Tract Urothelial Carcinoma – Subgroup Analysis of an Observational Study

Abstract: Abstract. Background

Cited by 2 publications

References 18 publications

European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update

European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update

Clinical and Biological Differences between Upper Tract Carcinoma and Bladder Urothelial Cancer, Including Implications for Clinical Practice

Contact Info

Product

Resources

About